Dearterialization of the Liver for Metastatic Cancer

McDermott, William V.; Paris, Allen; Clouse, Melvin E.; Meissner, William A.

doi:10.1097/00000658-197801000-00008

Cited by 28 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Liver metastases from carcinoid tumors have been treated with resection [22,23], enucleation [24,25], hepatic artery ligation [26], and total hepatic dearterialization [27,28]. Hepatic artery ligation and total hepatic dearterialization give a good symptomatic result in about 50% of patients treated [16][17][18], but the operations are followed by a significant mortality rate [16][17][18].…”

Section: Discussionmentioning

confidence: 99%

Temporary liver dearterialization in patients with metastatic carcinoid disease

et al. 1982

View full text Add to dashboard Cite

The surgical treatment of liver metastases from carcinoid tumors is burdened by a relatively poor symptomatic relief and a high mortality rate. Temporary liver dearterialization, separating the operative trauma from the temporary hepatic occlusion, may have advantages. We have utilized this treatment in 16 patients. The effect of treatment was registered in symptomatic relief, changes in urinary 5-HIAA, serotonin in platelet-poor plasma, and morphologic changes shown by angiography.Fourteen patients, who underwent only the dearterialization procedure, survived the immediate postoperative period, while 2 patients who had concomitant small bowel resection both died of complications, 1 and 3 months postoperatively, respectively. One patient died, 14 months postoperatively, of the carcinoid disease. All but 1 patient were free from symptoms for at least 6 months. Two patients have had no recurrence of the carcinoid syndrome for 34 and 42 months, respectively. A decrease in urinary 5-HIAA was seen after 6 months in 10 patients, serotonin declined in 7 patients, and angiography showed regression in 7 patients. The results of this study indicate that temporary liver dearterialization is a safe procedure with low mortality and good symptomatic relief from the carcinoid syndrome.Both primary and secondary liver tumors are chiefly supplied by blood from the hepatic artery, which was first shown by Segall in 1923 [1] and later confirmed by others [2,3]. Smaller tumors [4] and Supported by grants from the Swedish Medical Research Council (grant no. 04X-00712).

show abstract

Section: Discussionmentioning

confidence: 99%

Temporary liver dearterialization in patients with metastatic carcinoid disease

et al. 1982

View full text Add to dashboard Cite

show abstract

“…Three of the fifteen (20%) arterially ligated patients eventually developed sufficient tumor necrosis to warrant surgical drainage. Fortner [16] and McDermott [18] each reported one case of hepatic necrosis requiring surgical drainage, while Alsmerjo et al [4] reported one death from liver abscess which was not drained surgically.…”

Section: Discussionmentioning

confidence: 99%

The role of hepatic artery ligation and dearterialization with infusion chemotherapy in advanced malignancies in the liver

Berjian

Douglass

Nava

et al. 1980

Journal of Surgical Oncology

View full text Add to dashboard Cite

Because of limited benefits derived with the use of systemic chemotherapy, 15 patients with metastatic malignancy of the liver or hepatoma were treated by hepatic artery ligation (6) or dearterialization (9) and regional infusion chemotherapy. There were two postoperative deaths and three patients required surgical drainage of hepatic tumor liquefaction necrosis. The median survival was 14 months with two patients still living. The longest survivors were those patients with visceral leiomyosarcoma or carcinoid tumor. Five of the patients had failed to respond to previous chemotherapy, all showed a favorable response to this therapy. Rigid criteria for proper case selection have been developed which should reduce the operative mortality. Hepatic artery ligation is a therapeutic modality that can be of benefit to patients for whom no other satisfactory treatment is available.

show abstract

“… 7 Although follow-up biopsy demonstrated extensive necrosis in large tumors, more than half of the patients died within 6 months. McDermott et al 8 reported on a similar procedure in 1979 and, despite beneficial results in 3 of the 5 patients, extensive collaterals developed postoperatively that resupplied the tumors. By 1981, using a “catheter as a scalpel” had been proposed by Charles Dotter, 9 and Chuang and Wallace 10 described encouraging results embolizing a variety of liver tumors with gelfoam and coils.…”

Section: Evolution Of Transarterial Embolization Treatments For Hccmentioning

confidence: 99%

Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

et al. 2017

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (IHC) are primary liver cancers where all or most of the tumor burden is usually confined to the liver. Therefore, locoregional liver-directed therapies can provide an opportunity to control intrahepatic disease with minimal systemic side effects. The English medical literature and clinical trials were reviewed to provide a synopsis on the available liver-directed percutaneous therapies for HCC and IHC. Locoregional liver-directed therapies provide survival benefit for patients with HCC and IHC compared to best medical treatment and have lower comorbid risks compared to surgical resection. These treatment options should be considered, especially in patients with unresectable disease.

show abstract

Dearterialization of the Liver for Metastatic Cancer

Cited by 28 publications

References 19 publications

Temporary liver dearterialization in patients with metastatic carcinoid disease

Temporary liver dearterialization in patients with metastatic carcinoid disease

The role of hepatic artery ligation and dearterialization with infusion chemotherapy in advanced malignancies in the liver

Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Contact Info

Product

Resources

About